DexCom, Inc. , the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into ...
Also, we'll take this moment to debrief what current scientific evidence says about glucose as a measure of our metabolic health -- the very function of our bodies and how they use energy.
The global self-monitoring blood glucose devices market was valued at $8,490.79 million in 2019, and is projected to reach $11,991.98 million by 2027, growing at a CAGR of 4.2% from 2020 to 2027.